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Abstract To elucidate the molecular mechanisms by which hu-
man epidermal growth factor receptor/heregulin (HER2/HRG)
in£uence the migratory potential of breast cancer cells, we have
used phospho-speci¢c antibodies against c-Src kinase and focal
adhesion kinase (FAK). This study establishes that HER2/HRG
signaling selectively upregulates Tyr phosphorylation of c-Src at
Tyr-215 located within the SH2 domain, increases c-Src kinase
activity and selectively upregulates Tyr phosphorylation of FAK
at Tyr-861. HER2-overexpressing tumors showed increased lev-
els of c-Src phosphorylation at Tyr-215. These ¢ndings suggest
that HER2/HRG in£uence metastasis of breast cancer cells
through a novel signaling pathway involving phosphorylation
of FAK tyrosine 861 via activation of c-Src tyrosine 215.
. 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Human epidermal growth factor receptor 2 (HER2/neu) [1],
heregulin (HRG), a combinatorial HER ligand [2], and Src
kinases [3,4] have been implicated in the regulation of breast
cancer progression. Growth factor signaling regulates c-Src
kinase activity by altering the tyrosine phosphorylation of
speci¢c Tyr residues. Tyrosine phosphorylation at residues
Tyr-215 and Tyr-418 increases c-Src kinase activity, while
Tyr phosphorylation at Tyr-529 down regulates c-Src kinase
activity [4]. Focal adhesion kinase (FAK), a non-receptor ty-
rosine kinase and substrate of c-Src present in focal adhesions,
is implicated in the regulation of cell motility, adhesion, and
anti-apoptotic signaling [5,6]. Growth factors induce phos-
phorylation of FAK on a number of Tyr residues and each
of the FAK Tyr residues has been implicated in generating a
distinct signal. For example, FAK Tyr-397 in recruiting c-Src,
phosphoinositide 3P-kinase and p130CAS to focal adhesions;
FAK Tyr-576 and FAK Tyr-577 in upregulating FAK kinase
activity [7] ; FAK Tyr-925 in activating the Ras-mitogen-acti-
vated protein kinase pathway [8] ; and FAK Tyr-861 in Ras-
mediated transformation [9]. Cells lacking FAK are refractory
to platelet-derived growth factor- and epidermal growth fac-
tor-mediated motility signals [10].
Growth factor-mediated formation of motile structures in-
volves regulation of FAK tyrosine phosphorylation [11]. In-
terestingly, HRG or activated HER2 reorganize the cytoskel-
eton, and increase the metastatic potential of breast cancer
cells without an increase in the total tyrosine phosphorylation
of FAK, suggesting HER2 might use a distinct pathway to
regulate FAK [12,13]. However, very little information is
known on the molecular mechanisms by which HER2 and
HRG regulate Src and FAK signaling to alter the metastatic
potential of breast tumor cells. The results from this study
suggest that HRG and HER2 signaling selectively upregulates
tyrosine phosphorylation of c-Src at Tyr-215 located within
the SH2 domain, increases c-Src kinase activity and selectively
upregulates tyrosine phosphorylation of FAK at Tyr-861.
2. Materials and methods
2.1. Cell cultures, reagents and plasmids
MCF-7 human breast cancer cells, NIH 3T3 cells, and B104 (NIH
3T3 cells expressing kinase-activated HER2) [13] were maintained in
Dulbecco’s modi¢ed Eagle’s medium^F12 medium (1:1) supple-
mented with 10% fetal calf serum. Phospho-speci¢c antibodies against
FAK and Src were purchased from Biosource (Camarillo, CA, USA).
Antibodies against HER2 (#MS325-P) and recombinant HRG L-1
were purchased from Neomarkers (Fremont, CA, USA). Antibodies
against FAK (#F2918) and vinculin (#V913) were purchased from
Sigma (St. Louis, MO, USA). c-Src WT cDNA expression vector
(#21-114) was purchased from Upstate Biotechnology (Lake Placid,
NY, USA). Src mutant Y215F was constructed using the site-directed
mutagenesis kit from Stratagene (La Jolla, CA, USA) using the fol-
lowing primers: forward, AGCGGCGGTTTCTTCATCACCTC-
CCGCACCCAG and reverse, CTGGGTGCGGGAGGTGATGAA-
GAAACCGCCGCT.
2.2. Cell extracts, immunoblotting and immunoprecipitation
MCF-7 cells were serum-starved for 48 h and treated with di¡erent
concentrations of HRG (0.01 nM, 0.1 nM, or 1.0 nM). To prepare cell
extracts, cells were washed three times with phosphate-bu¡ered saline
(PBS) and then lysed with RIPA bu¡er (50 mM Tris^HCl, pH 7.5,
150 mM NaCl, 0.5% NP-40, 0.1% sodium dodecyl sulfate, 0.1% so-
dium deoxycholate, 1Uprotease inhibitor cocktail (Roche Biochemi-
cal) and 1 mM sodium vanadate) for 15 min on ice.
2.3. Src kinase assays
In vitro Src kinase assays were performed following the previously
described protocol [14]. Brie£y, c-Src kinase was immunoprecipitated
from 400 Wg of cell lysates treated with or without HRG. Immuno-
precipitates were washed three times with Triton X-100 lysis bu¡er
and three times with kinase bu¡er (20 mM HEPES pH 7.0, 10 mM
MgCl2, 1 mM dithiothreitol) and kinase reactions were performed
using 10 Wg of acid-denatured enolase as a substrate at 30‡C for 30
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min, and visualized by sodium dodecyl sulfate^polyacrylamide gel
electrophoresis followed by autoradiography.
2.4. Immuno£uorescence studies and confocal microscopy
For indirect immuno£uorescence studies, cells were blocked by in-
cubation with 10% normal goat serum in PBS for 1 h at ambient
temperature. Cells were then incubated for 1 h at ambient temperature
with polyclonal antibodies against FAK Tyr-861 or Src Tyr-215 and
with monoclonal antibodies against vinculin. After four washes with
PBS, cells were incubated with ALEXA-488- or £uorescein isothio-
cyanate-conjugated goat anti-mouse IgG or with ALEXA-546-conju-
gated goat anti-rabbit IgG (1:100 dilution, Molecular Probes, Eugene,
OR, USA) in 10% normal goat serum (in PBS). Control cells were
treated only with the secondary antibody. Slides were analyzed by
confocal microscopy.
3. Results
3.1. HER2/HRG signaling uniquely upregulates Src
phosphorylation at Tyr-215
To examine the possible participation of Src kinase in
HER2/HRG signaling, we utilized three well-characterized
phospho-speci¢c antibodies [15^17], which uniquely recognize
Tyr-215, Tyr-418 and Tyr-529 on Src. We used MCF-7 breast
cancer cells, which are known to express HER2 and HER3.
MCF-7 breast cancer cells were treated with HRG, a ligand
that is known to activate the HER2 pathway [18,19]. HRG
selectively enhanced c-Src Tyr-215 phosphorylation in a dose-
and time-dependent manner (Fig. 1A). The highest level of
phosphorylation was observed at a concentration of 1 nM,
which was previously shown to elicit a migratory phenotype
in breast cancer cells [12]. Interestingly, there was no signi¢-
cant change in the phosphorylation of c-Src at Tyr-418, which
was earlier linked to activation of Src kinase by a number of
physiological signals [4]. Increased c-Src Tyr-215 phosphory-
lation correlated well with Src kinase activity as assessed by in
vitro kinase assay (Fig. 1B). Confocal microscopy analysis of
HRG-treated MCF-7 cells also demonstrated elevated c-Src
Tyr-215 phosphorylation (Fig. 1C, bottom panel, green col-
or). HRG treatment signi¢cantly induced the formation of
motile structures such as ru¥es, and importantly, a signi¢cant
pool of activated c-Src Tyr-215 was localized in these struc-
tures. These results suggest that HRG may activate c-Src ki-
nase via phosphorylation of Tyr-215 and that functionally
activated c-Src kinase localizes to ru¥es.
3.2. HRG induces phosphorylation of FAK at Tyr-861 in
a c-Src kinase-sensitive manner
We next examined the functional consequence of HRG-in-
duced stimulation of c-Src kinase by examining the phosphor-
ylation status of a known downstream c-Src substrate, FAK.
We used several commercially available Tyr site-speci¢c anti-
bodies against FAK Tyr sites [9]. We did not observe any
signi¢cant increase in the phosphorylation of FAK at auto-
phosphorylation site Tyr-397 (Fig. 2A). We also did not no-
tice any increase in the Tyr phosphorylation of FAK Tyr-577,
Tyr-925, rather, we observed a slight decrease in the level of
tyrosine phosphorylation of these sites with an increase in
HRG dose. Interestingly, HRG transiently stimulated the lev-
el of Tyr phosphorylation of FAK Tyr-861 in a dose-depen-
Fig. 1. HRG-induced Tyr phosphorylation of Src. A: Immunoblot analysis. MCF-7 cells were treated with 0.01 nM, 0.1 nM, or 1 nM HRG
for the indicated times, and total lysates (200 Wg) were analyzed by immunoblotting with site-speci¢c antibodies that recognize distinct Tyr sites
on Src kinase. B :In vitro kinase analysis. MCF-7 cells were treated with or without HRG and kinase assays were performed using enolase as
a substrate. C: Confocal microscopy analysis. Localization of Src Tyr-215 was studied in MCF-7 cells treated with or with out HRG for 30
min. Src Tyr-215 is shown in green and phalloidin, a marker of F-actin-containing structures, is shown in red. Con indicates serum-starved
MCF-7 cells not treated with HRG.
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dent manner (Fig. 2A). HRG increased FAK Tyr-861 phos-
phorylation in a time-dependent manner with maximal acti-
vation at 15 min (Fig. 2B). The HRG-mediated increase in
FAK phosphorylation at Tyr-861 was blocked by pretreat-
ment of cells with the Src inhibitor PP2 (Fig. 2C). To mech-
anistically link HRG-mediated Src Tyr-215 phosphorylation
to FAK Tyr-861 phosphorylation, we generated a c-Src con-
struct in which tyrosine of Src at 215 was mutated to phenyl-
alanine (Y215F). Using this mutant we analyzed HRG-medi-
ated signaling to FAK at Tyr-861. The results suggest that
expression of wild type Src substantially increased both basal
and HRG-mediated phosphorylation of FAK at Tyr-861
while expression of the Src Y215F mutant failed to increase
HRG-mediated upregulation of phosphorylation of FAK at
Tyr-861 (Fig. 2D). Confocal microscopy analysis also showed
that HRG induced phosphorylation of FAK Tyr-861 (Fig.
2E, green color, middle panel) as compared to control (Fig.
2E, left panel). Furthermore, HRG-induced ru¥e formation
as well as FAK Tyr-861 phosphorylation was blocked by
pretreatment of cells with the Src-speci¢c inhibitor PP2 (Fig.
Fig. 2. HRG-induced tyrosine phosphorylation of FAK. A: Western blot analysis. MCF-7 cells were treated with 0.01 nM, 0.1 nM or 1 nM
HRG for 30 min, and total lysates (200 Wg) were analyzed by Western blotting with site-speci¢c antibodies that recognize distinct sites on
FAK. B: MCF-7 cells were treated with 1 nM HRG for indicated periods of time, equal amount of protein was immunoprecipitated with
FAK antibody. Blots were probed with phospho-speci¢c antibody against FAK Tyr-861. Blot was stripped and reprobed with FAK antibody
C: MCF-7 cells were pretreated with or without the Src inhibitor PP2 for 30 min and then stimulated with 1 nM HRG for 15 min. Cell lysates
were immunoprecipitated with FAK antibody, Western-blotted with phospho-speci¢c FAK Tyr-861 antibody. D: MCF-7 cells were transfected
with vector, Src wild type or Src mutant (SrcY215F) using Fugene-6 reagent in serum-free medium. After 24 h, cells were treated with 1 nM
HRG for 15 min and equal amount of cell lysate was immunoprecipitated with FAK antibody followed by Western blotting with a phospho-
speci¢c antibody against FAK Tyr-861. Total lysate was run on a separate gel and analyzed by Western blotting using Src antibody (bottom
panel) to visualize the expression of transfected Src constructs (lanes 2^5) compared to vector-transfected control (lane 1). E: Confocal micros-
copy analysis. Localization of FAK Tyr-861 was studied in MCF-7 cells treated with or without HRG for 30 min. As indicated some cells
were pretreated with the Src inhibitor PP2 for 30 min before the addition of HRG. FAK Tyr-861 is shown in green, and phalloidin, a marker
of F-actin-containing structures, is shown in red. Con indicates serum-starved MCF-7 cells not treated with HRG.
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2E, right panel) [20]. Together these results suggest that
HRG-induced stimulation of FAK Tyr-861 phosphorylation
might be mediated by c-Src kinase via its activation by phos-
phorylation at Tyr-215.
3.3. Activated HER2 modulates phosphorylation of Src at
Tyr-215 and FAK at Tyr-861
We next analyzed the e¡ect of HER2 overexpression on the
status of Src Tyr-215 and FAK Tyr-861 using the NIH 3T3
cell line and a well-characterized NIH 3T3 cell line, B104, that
expresses activated HER2 [13]. B104 cells exhibited elevated
phosphorylation of c-Src Tyr-215 and FAK Tyr-861 com-
pared to the phosphorylation in control NIH 3T3 cells. Min-
imal or no change was found in the status of tyrosine of FAK
at Tyr-577, Tyr-925 and Tyr-397. To con¢rm the presence and
subcellular localization of FAK Tyr-861 phosphorylation in
NIH 3T3 and B104 cells, we performed immuno£uorescence
studies followed by confocal microscopy. The results showed
that despite a high level of FAK Tyr-861 phosphorylation in
B104 cells, its location was primarily in the cytoplasm (Fig.
3B, thin arrows), as compared to a lower overall amount of
phosphorylated FAK Tyr-861 distributed in a distinct dot-like
pattern in the parental NIH 3T3 cells (Fig. 3B, thick arrows).
Moreover, distinct di¡erences in the cell surface morphology
were also noticed (very well spread in NIH 3T3 cells vs. bi-
polar in B104 cells) and the amount of FAK Tyr-861 per cell
surface unit was much greater in B104 cells than in parental
NIH 3T3 cells. These ¢ndings suggest that active HER2 sig-
naling mimics the events of HRG signaling including phos-
phorylation of c-Src Tyr-215 and FAK Tyr-861.
Fig. 3. Analysis of signaling pathways in NIH 3T3 cells expressing constitutively activated HER2. A: Western blot analysis. NIH 3T3 cells and
B104 cells (NIH 3T3 cells expressing activated HER2) [13] were lysed and analyzed using phospho-speci¢c antibodies against the indicated mol-
ecules. B: Confocal microscopy analysis. The status and localization of FAK Tyr-861 was studied in NIH 3T3 cells and B104 cells. FAK Tyr-
861 is shown in red and vinculin, a marker of focal adhesions, is shown in green. Thick arrows point to localization of FAK Tyr-861 in dot-
like focal adhesions in NIH 3T3 cells. Empty arrows point to the cytoplasmic localization of FAK Tyr-861.
Fig. 4. Upregulation of tyrosine phosphorylation of Src at Tyr-215 in HER2-overexpressing breast tumors. Western blot analysis. Lysates from
normal and breast tumor specimens were analyzed by immunoblotting with site-speci¢c antibodies that recognize distinct Tyr sites on Src and
FAK kinases. Blots were probed with anti-HER2 antibody to analyze the status of HER2 in tumors. Vinculin was used as a loading control.
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3.4. Upregulation of Src Tyr-215 phosphorylation in breast
tumors
To con¢rm the in vitro cell culture data, we analyzed the
status of tyrosine phosphorylation of c-Src in a small number
of breast tumor specimens. Of the six pairs of breast tumor
samples analyzed, ¢ve tumors with high HER2 levels exhib-
ited increased levels of tyrosine phosphorylation on Src Tyr-
215 compared to tumors without HER2 overexpression or
normal controls (Fig. 4). A modest increase in the level of
Tyr-418 was also seen in tumors while little change in the
Tyr-529 was observed. Results show the coexistence of in-
creased levels of phosphorylation of Src at Tyr-215 and
FAK at Tyr-861 in three of six HER2-overexpressing tumors
(Fig. 4). These results provide proof of principle that the Src
Tyr-215^FAK Tyr-861 pathway we identi¢ed in the MCF-7
cell culture model also occurs in breast tumors.
4. Discussion
Src kinase activity has previously been shown to be elevated
in HER2-induced mammary tumors [21]. Our results suggest
that Src kinase signaling might play a unique role in signaling
by HRG and HER2. HRG activated c-Src via tyrosine phos-
phorylation of Tyr-215 located in the SH2 domain in a dose-
and time-dependent manner and increased Src kinase activity.
Furthermore, overexpression of constitutively active HER2
also induced phosphorylation of c-Src Tyr-215. Activated
c-Src Tyr-215 distinctly localized to actin-containing motile
structures such as ru¥es in HRG-treated MCF-7 cells and
in B104 cells which express activated HER2. In the literature,
we could ¢nd only one other report showing phosphorylation
of Src Tyr-215 by a growth factor, platelet-derived growth
factor, and such phosphorylation was reported to result in
activation of Src kinase due to disruption of SH2 binding to
the C-terminal region of c-Src [22]. Our results support the
earlier observation of tyrosine phosphorylation of c-Src at
Tyr-215 by growth factors and further suggest that c-Src
Tyr-215 phosphorylation may have a unique e¡ect on the
localization of c-Src and its substrate speci¢city.
Despite an enhancement of the c-Src kinase activity by Tyr
phosphorylation at Tyr-215 by HRG, only selective change in
the phosphorylation of the Src substrate FAK at Tyr-861 was
observed. Earlier studies demonstrated that FAK Tyr-861 is a
major site of phosphorylation by Src kinase [23]. Vascular
endothelial growth factor signaling-mediated endothelial cell
migration and anti-apoptosis functions were shown to involve
Tyr phosphorylation of FAK at 861 via Src kinase [18]. Re-
cently, phosphorylation of FAK at Tyr-861 was shown to
correlate with Ras-induced transformation of ¢broblasts [9].
The results of this study suggest that FAK phosphorylation at
Tyr-861 also represents a mechanism by which both HRG
and activated HER2 may in£uence the malignant phenotype
of epithelial cells since blockage of Src kinase activity by a
selective inhibitor PP2 resulted in the reduction of ru¥e for-
mation induced by HRG. The ¢ndings that HRG and HER2
activated Src kinase and that the Src inhibitor PP2 blocked
both the upregulation of FAK Tyr-861 phosphorylation and
HRG-mediated cytoskeletal changes suggest that the Src Tyr-
215 to FAK Tyr-861 pathway may be important for HRG
and HER2 signaling to mediate cytoskeletal changes.
c-Src is also known to utilize Tyr-397, an autophosphory-
lation site, to associate with FAK [6]. Since HRG did not
cause any changes in the phosphorylation of FAK Tyr-397,
HRG- and HER2-activated c-Src may interact with FAK via
other interacting sites, and selectively phosphorylate c-Src at
Tyr-861. In this context, v-Src was previously shown to induce
FAK Tyr phosphorylation, independently of Tyr-397 phos-
phorylation [24]. Identi¢cation of HRG signaling to FAK ki-
nase via phosphorylation of the SH2 domain raises the pos-
sibility that the phospho antibodies against c-Src Tyr-215 may
serve as a prognostic marker. However, a larger study would
need to be conducted to establish the signi¢cance of these
tools. In summary, our results suggest that HER2 and
HRG systems uniquely regulate signaling from focal adhesion
complexes through selective phosphorylation of c-Src Tyr-215
and FAK Tyr-861.
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